Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: A 6-month open-label, single-arm pilot study

Arthritis and Rheumatology

Volumn 66, Issue 11, 2014, Pages 3241-3243

  Brik, Riva ^a   Butbul Aviel, Yonatan ^a   Lubin, Sari ^b   Ben Dayan, Eliad ^b   Rachmilewitz Minei, Tamar ^b   Tseng, Lillian ^c   Hashkes, Philip J ^d  

^a MEYER CHILDREN S HOSPITAL   (Israel)

^b Novartis Pharma   (Israel)

^c NOVARTIS PHARMA AG   (Switzerland)

^d SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; COLCHICINE; RILONACEPT; SERUM AMYLOID A; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY;

ARTICLE; CHILDHOOD DISEASE; CINCA SYNDROME; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE SEDIMENTATION RATE; FAMILIAL MEDITERRANEAN FEVER; HUMAN; INFECTION; NEOPLASM; OPEN STUDY; OPPORTUNISTIC INFECTION; PHARYNGITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOCIAL PSYCHOLOGY; STREPTOCOCCUS INFECTION; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; TREATMENT RESPONSE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; ADOLESCENT; CHILD; CLINICAL TRIAL; DOSE RESPONSE; DRUG RESISTANCE; FEMALE; IMMUNOLOGY; MALE; METABOLISM; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ANTIBODIES, MONOCLONAL; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CHILD; COLCHICINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMANS; INTERLEUKIN-1BETA; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PILOT PROJECTS; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84925581544     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38777     Document Type: Article

References (8)

1. Ben-Chetrit E, Ozdogan H,. Non-response to colchicine in FMF: definition, causes and suggested solutions. Clin Exp Rheumatol 2008; 26 Suppl 50: S49-51.
2. Ozen S, Bilginer Y, Aktay Ayaz N, Calguneri M,. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol 2011; 38: 516-8.
3. Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park G, et al., Rilonacept for colchicine-resistant or intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med 2012; 157: 533-41.
4. Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, et al., Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997; 40: 1879-85.
5. Landgraf M, Abetz L, Ware JE,. The CHQ user's manual. Boston: The Health Institute, New England Medical Center; 1996.
6. Lachmann H, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al, for the Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360: 2416-25.
7. Gattorno M, Obici L, Meini A, Torney V, Abrams K, Davis N, et al., Efficacy and safety of canakinumab in patients with TNF receptor associated periodic syndrome (TRAPS) [abstract]. Ann Rheum Dis 2013; 71 Suppl 3: 289.
8. Ruperto N, Brunner H, Quartier P, Constantin T, Wulffraat N, Horneff G, et al, for the PRINTO and PRCSG. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2396-406.